Biotech “Mapmaker” Immunai Launches With $20M to Chart the Immune System
Xconomy New York — It may seem like an unlikely link but the body’s response to arthritis may hold answers for better cancer drugs, says Luis Voloch, chief technology officer of startup Immunai. Immune cells respond to both conditions, but in different ways. Insights into the response for one disease could…
bubmagMay 14, 2020